logo
logo

Novalis Biotech Closes €25 Million Biotech Acceleration Fund

Novalis Biotech Closes €25 Million Biotech Acceleration Fund

06/30/21, 6:36 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/BE.svgghent
Money raised
€25 million
Novalis Biotech, an early-stage venture capital investor in technologies aimed at revolutionizing healthcare, announced today the closing of its €25 million second fund, the Novalis Biotech Acceleration Fund. Both new and returning investors have participated in the fundraising. The second fund investor base includes institutional investors, such as Participatie Maatschappij Vlaanderen (PMV), family offices, as well as HNWIs.

Company Info

Company
Novalis Biotech Acceleration
Location
ghent, east flanders, belgium
Additional Info
Novalis Biotech (Ghent, Belgium) is an early-stage venture capital investor in technologies that revolutionize healthcare. The company’s core competence lies in digitalization in the life sciences with a focus on capital light “enabling technologies” such as bioinformatics, AI, genomics, personalized medicine, research or manufacturing tools and diagnostics. For more information, please visit www.noval.is.